Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method
Titel:
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method
Auteur:
Haas, M. Waldschmidt, D.T. Stahl, M. Reinacher-Schick, A. Freiberg-Richter, J. Fischer von Weikersthal, L. Kaiser, F. Kanzler, S. Frickhofen, N. Seufferlein, T. Dechow, T. Mahlberg, R. Malfertheiner, P. Illerhaus, G. Kubicka, S. Abdul-Ahad, A. Snijder, R. Kruger, S. Westphalen, C.B. Held, S. von Bergwelt-Baildon, M. Boeck, S. Heinemann, V.